How does Johnson & Johnson (JNJ) make money?

Johnson & Johnson (JNJ) generates revenue primarily from Innovative Medicine, which accounted for 64.4% of total revenue in TTM through Q1 2026. The company reported $96.68B in revenue and converted 21.4% of it into net profit, equivalent to roughly $20.74B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reported a gross profit margin of 70% in TTM through Q1 2026, equivalent to $67.69B in gross profit on $96.68B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reported an operating profit margin of 26.4% in TTM through Q1 2026, equivalent to $25.48B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reported a net profit margin of 21.4% in TTM through Q1 2026, equivalent to $20.74B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Johnson & Johnson (JNJ) profitable?

Yes. Johnson & Johnson (JNJ) reported $20.74B in net income for TTM through Q1 2026, with a net profit margin of 21.4%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Johnson & Johnson (JNJ) invest in research and development?

Johnson & Johnson (JNJ) invested $14.98B in research and development during TTM through Q1 2026, roughly 15.5% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Johnson & Johnson (JNJ) spend on capital expenditures?

Johnson & Johnson (JNJ) spent $5.07B on capital expenditures (CapEx) during TTM through Q1 2026, roughly 5.2% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Johnson & Johnson (JNJ) generate?

Johnson & Johnson (JNJ) generated $17.80B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 18.4%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) had an effective tax rate of 15.1% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reports revenue across 2 reportable product segments, led by Innovative Medicine at 64.4% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Johnson & Johnson (JNJ) generate most of its revenue?

UNITED STATES is the largest geographic market for Johnson & Johnson (JNJ), accounting for 49.9% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Johnson & Johnson Makes Money: 2026 Visual Revenue Map

Johnson & Johnson (JNJ) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported March 31, 2026).

Johnson & Johnson (JNJ) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Johnson & Johnson (JNJ) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Innovative Medicine	$62.24B	64.4%
MedTech	$34.44B	35.6%
Total	$96.68B	100%

Innovative Medicine$62.24B
MedTech$34.44B
Total$96.68B

Johnson & Johnson (JNJ) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Johnson & Johnson (JNJ), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$41.45B	49.9%
Europe	$22.27B	26.8%
Asia-Pacific, Africa	$14.31B	17.2%
Western Hemisphere, excluding U.S.	$5.00B	6%
Total	$83.03B	100%

UNITED STATES
Europe
Asia-Pacific, Africa
Western Hemisphere, excluding U.S.
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Johnson & Johnson (JNJ) reports revenue across 2 operating segments; the largest segment was Innovative Medicine at 64.4%, followed by MedTech (35.6%). Separately, by end-market geography, UNITED STATES accounted for 49.9% of revenue, followed by Europe (26.8%) and Asia-Pacific, Africa (17.2%).

Frequently asked questions

Data & methodology

Johnson & Johnson (JNJ) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation